Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMAvax-EGF in Combination With Standard Therapy for Metastatic Colorectal Cancer
NCT06011772Phase 1Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2023
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of cimavax egf in colorectal cancer (CRC) (3 cohorts), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Immunogenicity of vaccine. Started Dec 2023; status: active, not recruiting.
02
Drugs
cimavax egf
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06011772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011772.